ASX Announcements

20th Oct Appendix 4C - Quarterly
20th Oct Notice of Annual General Meeting/Proxy Form
20th Oct Appendix 4G and Corporate Governance Statement
20th Oct Annual Report to Shareholders
18th Oct Replacement Appendix 3B
16th Oct Initial Director's Interest Notice
13th Oct Appendix 3B
13th Oct Prospectus
10th Oct Net Tangible Asset Backing
6th Oct $1.2M Capital Raising
2nd Oct Update on Capital Raising
27th Sep Suspension from Official Quotation
25th Sep Trading Halt
22nd Sep Omni Innovation Executes Chinese Licence Agreement
20th Sep Net Tangible Asset Backing
1st Sep Appendix 4E and Full Year Statutory Accounts
28th Aug Revised Medical Honey Investment Structure
16th Aug Omni Innovation Enters Chinese Distribution Agreement with Eagle Health
14th Aug Net Tangible Asset Backing
14th Aug Trading Halt
31st Jul Appendix 4C - Quarterly
14th Jul Net Tangible Asset Backing
5th Jul Change of Director's Interest Notice x 3
4th Jul Prospectus
4th Jul Appendix 3B
26th Jun Results of General Meeting
26th Jun Accelerating Portfolio Progress
15th Jun Net Tangible Asset Backing
31st May Investor Presentation
30th May Southern Cross University Collaboration with Medic Honey
25th May Notice of General Meeting/Proxy Form
18th May Appointment of Leading Medicinal Cannabis Advisor
12th May Net Tangible Asset Backing
9th May Change in Substantial Holding
9th May Change of Director's Interest Notice x 3
9th May Replacement Appendix 3B
5th May EVE Capital Raising Completed
5th May Appendix 3B
5th May Prospectus
3rd May EVE Capital Raising Oversubscribed
2nd May Reinstatement to Official Quotation
1st May Eve Invests in Pioneering Cannabis Honey & Tea Tree Oil Co
28th Apr Appendix 4C - Quarterly
21st Apr LNK: Change of Perth Address for Shareholder Purposes
21st Apr Update on Capital Raising
18th Apr Update on Capital Raising
13th Apr Net Tangible Asset Backing
10th Apr Update on Capital Raising
3rd Apr Update on Capital Raising
27th Mar Voluntary Suspension
23rd Mar Trading Halt
23rd Mar Omni Innovation - US Manufacturer Appointed
22nd Mar Omni Innovation Completes UK Licence Agreement
14th Mar Net Tangible Asset Backing
8th Mar Omni Innovation US Update
1st Mar Omni Innovation - US Patent Notice of Allowance Received
28th Feb Omni Innovation Update
28th Feb Half Yearly Report and Accounts
14th Feb Results of Meeting
13th Feb Net Tangible Asset Backing
30th Jan Appendix 4C - Quarterly
25th Jan Sales Results Exceed Expectations for Faulding GlucoControl
17th Jan Change of Director's Interest Notice
12th Jan Notice of General Meeting/Proxy Form
11th Jan Change in Substantial Holding
11th Jan Net Tangible Asset Backing

Adobe Acrobat Reader 5.0 or later needed to view PDF files. Get Acrobat Reader